Risk Factors Affecting Growth in Thalassemic Children at AUCH

Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Thalassemia Majors (Beta-Thalassemia Major) Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Thalassemia beta-Thalassemia

Age range

12 month–18 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).
Receiving regular blood transfusions as part of standard management at AUCH.
Attending the hematology unit for at least one year prior to enrollment.

Exclusion criteria

• Children with other types of thalassemia.

Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.
Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.

Treatment and study plan

Non-interventional assessment of growth and risk factors in thalassemic children

Other

No therapeutic intervention is applied. The study involves only observational assessment of clinical history, anthropometric measurements, laboratory investigations, and growth parameters in thalassemic children. This distinguishes it from interventional studies.

Primary outcomes

Growth parameters: Z-scores for height-for-age, weight-for-age, BMI-for-age

Time frame: 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Aya Sale Sadek

CONTACT

[email protected]

+20 1555112872

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

The Effect of Different Risk Factors on Growth Parameters of Thalassemic Patients in Assiut University Children Hospital

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Apr 3, 2026
Registry last updated: Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting